[A clinical study of tiapride in ten patients with chronic respiratory failure and in ten patients before fiberoptic bronchoscopy (author's transl)].
Ten patients with chronic respiratory failure (PaO2 = 56,19 +/- 10,54; PaCO2 = 49,17 +/- 7,31 torr) were given intramuscular injections of tiapride, Changes in alveolar ventilation were assessed clinically and by monitoring blood gases. No adverse effects were recorded. PaO2 was similar before and one hour after tiapride. There was no hypoventilation but, on the contrary, a slight decrease in PaCO2 (49,17 +/- 7,3 and 47,10 +/- 7,3 torr) and a significant increase in pH (7,358 +/- 0,023 and 7,378 +/- 0,028; p less than 0,05). Tiapride was also given to ten patients before fiberoptic bronchoscopy. Endoscopy was well tolerated in eight patients, in six there was no anxiety, and in all normal vigilance was retained.
D000328:Adult; D000368:Aged; D001549:Benzamides / Q000008:administration & dosage*; D001784:Blood Gas Analysis; D001999:Bronchoscopy; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D005260:Female; D005336:Fiber Optic Technology; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D011292:Premedication; D012131:Respiratory Insufficiency / Q000188:drug therapy*; D013976:Tiapamil Hydrochloride / Q000008:administration & dosage* / Q000009:adverse effects
D001549:Benzamides; D013976:Tiapamil Hydrochloride
Etude clinique du tiapride injectable chez l'insuffisant respiratoire chronique et comme prémédication aux fibroscopies.